English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16909/19260 (88%)
Visitors : 7601222      Online Users : 230
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/28643


    標題: PET Imaging of beta-Glucuronidase Activity by an Activity-Based I-124-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy
    作者: Su, Yu-Cheng
    Cheng, Ta-Chun
    Leu, Yu-Ling
    Roffler, Steve R.
    Wang, Jaw-Yuan
    Chuang, Chih-Hung
    Kao, Chien-Han
    Chen, Kai-Chuan
    Wang, Hsin-Ell
    Cheng, Tian-Lu
    貢獻者: 藥學系
    關鍵字: ANTITUMOR-ACTIVITY
    DRUG DEVELOPMENT
    CANCER-THERAPY
    ENZYME
    ACTIVATION
    TUMORS
    DOXORUBICIN
    EXPRESSION
    MICE
    CATALYSIS
    日期: 2014-12
    上傳時間: 2015-05-06 21:23:37 (UTC+8)
    出版者: Amer Assoc Cancer Research
    摘要: Beta-glucuronidase (beta G) is a potential biomarker for cancer diagnosis and prodrug therapy. The ability to image beta G activity in patients would assist in personalized glucuronide prodrug cancer therapy. However, whole-body imaging of beta G activity for medical usage is not yet available. Here, we developed a radioactive beta G activity-based trapping probe for positron emission tomography (PET). We generated a I-124-tyramine-conjugated difluoromethylphenol beta-glucuronide probe (TrapG) to form I-124-TrapG that could be selectively activated by bG for subsequent attachment of I-124-tyramine to nucleophilic moieties near beta G-expressing sites. We estimated the specificity of a fluorescent FITC-TrapG, the cytotoxicity of tyramine-TrapG, and the serum half-life of I-124-TrapG. beta G targeting of I-124-TrapG in vivo was examined by micro-PET. The biodistribution of I-131-TrapG was investigated in different organs. Finally, we imaged the endogenous bG activity and assessed its correlation with therapeutic efficacy of 9-aminocamptothecin glucuronide (9ACG) prodrug in native tumors. FITC-TrapG showed specific trapping at beta G-expressing CT26 (CT26/m beta G) cells but not in CT26 cells. The native TrapG probe possessed low cytotoxicity. I-124-TrapG preferentially accumulated in CT26/m beta G but not CT26 cells. Meanwhile, micro-PET and whole-body autoradiography results demonstrated that I-124-TrapG signals in CT26/m beta G tumors were 141.4-fold greater than in CT26 tumors. Importantly, Colo205 xenografts in nude mice that express elevated endogenous beta G can be monitored by using infrared glucuronide trapping probes (NIR-TrapG) and suppressed by 9ACG prodrug treatment. I-124-TrapG exhibited low cytotoxicity allowing long-term monitoring of bG activity in vivo to aid in the optimization of prodrug targeted therapy. (C) 2014 AACR.
    Appears in Collections:[藥學系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML342View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback